IMI’s OncoTrack project developed colon cancer models which allow researchers to more accurately predict the effect of drugs on different types of colon cancer tumours. This and other project outputs are already helping some doctors in choosing the right drug for the right patient, and could lead to more effective treatments in the future.
Scientists have identified five subtypes of diabetes, a finding that will pave the way for more personalised treatments for the disease. Patients in the different groups have different risk levels for certain complications associated with diabetes, such as kidney damage and eye disease. The work was funded in part by IMI through the projects BEAT-DKD and RHAPSODY.
Lhasa Limited is an SME specialising in the development of computer-based systems for use in research on toxicology and related sciences. The company is a partner in four IMI projects. Research Leader Katharine Briggs spoke to the IMI Programme Office about the benefits of taking part in IMI projects, and gave some tips for SMEs thinking of applying for IMI support.
The Innovative Medicines Initiative (IMI) project EUPATI built a much-needed programme for patient involvement in medicines research and development, and has been a game changer for patient empowerment in Europe, building a movement that will long outlive the project itself. Today, patients in Europe and beyond are benefitting from the project.
IMI's European Lead Factory project has created an integrated platform which is providing an innovative range of free services, expertise and a huge collection of compounds for researchers who are developing new drugs to treat all types of human diseases.
A potential drawback of clinical trials of new drugs is that they do not always reflect how well these will work in the 'real world'. IMI's GetReal project brought together key stakeholders to help add more such evidence into the design of trials, increasing confidence in new medicines and helping to get them to patients more quickly.
IMI’s RADAR-CNS project has recruited the first participants in the depression component of its study. RADAR-CNS aims to develop new ways of measuring major depressive disorder, epilepsy and multiple sclerosis using wearable devices and smartphone technology. The first study participants have received FitBit Charge 2 devices and smartphone apps.
IMI’s Mofina project has developed a portable device which can test for deadly Ebola in 75 minutes or less, eliminating the need to take suspected Ebola patients to treatment centres far away of their communities. In an interview, the project coordinator explains how Mofina’s success will save lives, and help contain future outbreaks.